

CURRICULUM VITAE

Nirav S. Patel, M.D.

Collaborative Neuroscience Network, Inc.
2600 Redondo Avenue, Suite 500
Long Beach, CA 90806
Tel. (866) 787-4257

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Site Liaison
Tel. (866) 669-0234
Fax (208) 575-3169
Email: clinicaltrials@btheodore.com

AFFILIATIONS:

Collaborative Neuroscience Network, Inc.
12772 Valley View Street, Suite 3
Garden Grove, CA 92845

Collaborative Neuroscience Network, Inc.
19401 S. Vermont Avenue, Suite F-100
Torrance, CA 90502

Ocean View Psychiatric Health Facility
2600 Redondo Avenue, Suite 500
Long Beach, CA 90806

Southland Neurologic Associates, Inc.
3791 Katella Avenue, Suite 106
Los Alamitos, CA 90720

Los Alamitos Medical Center
3751 Katella Ave
Los Alamitos, CA 90720

Long Beach Memorial Medical Center
2801 Atlantic Avenue
Long Beach, CA 90806

Community Hospital of Long Beach
1720 N. Termino Ave
Long Beach, California 90804

Harbor-UCLA Medical Center
1000 W. Carson Street
Torrance, California 90502

EDUCATION:

1985-1992 Biomedical Sciences Accelerated Program, University of California at Riverside and University of California at Los Angeles

1989 Bachelor of Science in Biomedical Sciences
University of California at Riverside

1992 Doctor of Medicine
University of California at Los Angeles School of Medicine

INTERNSHIPS, FELLOWSHIPS AND RESIDENCIES:

1992-1993 Internal Medicine Internship
Harbor-UCLA Medical Center, Torrance, CA

1993-1996 Neurology Residency (Adult)
Harbor-UCLA Medical Center, Torrance, CA

1996 Transcranial Doppler and Cerebral Blood Flow laboratory
University of California at Los Angeles

1996-1997 Stroke Fellowship
Harbor-UCLA Medical Center, Torrance, CA

CERTIFICATIONS:

American Board of Psychiatry and Neurology: 1999

Medical Board of California, Expiration: August 2007

National Board of Medical Examiners Part II: 1992

National Board of Medical Examiners Part I: 1991

PROFESSIONAL EXPERIENCE:

Principal Investigator, Collaborative Neuroscience Network, Inc. 2007 – Present

Private Practice, Southland Neurologic Associates, Los Alamitos, CA 2004 – Present

Clinical Faculty, Department of Neurology, Harbor-UCLA Medical Center: 1997 to Present

Assistant Clinical Professor, Department of Neurology, David Geffen School at Medicine at UCLA, 2003

PROFESSIONAL EXPERIENCE (continued):

Adult Primary Care Nurse Practitioner Program Faculty, Harbor-UCLA Medical Center: 1997-2003

Department of Family Medicine Faculty, School of Osteopathy, Pacific Hospital of Long Beach: 1999-2000

Biomedical Program Faculty, Neuroscience class, University of California at Riverside: 1998-2002

INVESTIGATOR EXPERIENCE:

Alzheimer's Disease • Diabetic Neuropathy • Osteoarthritis • Osteoporosis • Epilepsy
Chronic Low Back Pain • Migraine • Multiple Sclerosis • Pain • Parkinson's Disease
Post-Herpetic Neuralgia • Schizophrenia • Stroke

ADDITIONAL TREATMENT EXPERIENCE:

Chronic Pain • Fibromyalgia • Insomnia • Restless Legs Syndrome (RLS)

CLINICAL TRIAL EXPERIENCE:

Alzheimer's Disease

A 24 Week Open-Label Extension to Study XXX A 24 Week, Prospective, Randomized, Parallel-Group, Double-Blind, Multi-center Study Comparing the Effects of XXX vs. XXX on Activities of Daily Living and Cognition in Patients with Severe Dementia of the Alzheimer's Type (ACTION)

A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Efficacy And Safety Trial Of XXX in Patients With Mild To Moderate Alzheimer's Disease Who Are Apolipoprotein E 4 Non-Carriers Carriers

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral XXX in Alzheimer's Disease

Epilepsy

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial of XXX Controlled Release Formulation as Adjunctive Therapy in Adult Subjects with Partial onset Seizures

A Phase III, Multi-center, Open-Label Study Designed to Assess the Safety and Tolerability of Intravenously Administered XXX in Adult Subjects with Epilepsy. This Study will Include a 28 day Lead-in Period, a Confinement Period (up to 7 days and 6 nights) and a 28 day Follow-up Period

CLINICAL TRIAL EXPERIENCE (continued):

A Phase III Study that is Analyzing the Effectiveness and Safety of XXX Injections for Patients with Epilepsy that Receive Antiepileptic Drugs, but Still Experience Acute Repetitive Seizures (Bouts or Clusters of Seizures) that Require Treatment

A Double-Blind, Randomized, Historical-Controlled, Multi-Center Efficacy and Safety Study of XXX as Monotherapy in Patients With Refractory Partial Seizures & An Open-Label Multi-Center Extension Study to Determine Long Term Safety and Efficacy of XXX as Monotherapy in Patients With Partial Seizures

A Conversion to Monotherapy for Adults with Epilepsy Experiencing Partial Seizures (with or without Secondary Generalization), A Historical-controlled, Multi-center, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to XXX Monotherapy in Subjects with Partial-onset Seizures

A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of XXX, XXX, and XXX as Adjunctive Therapy in Subjects with Partial Onset Seizures

A Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of XXX Monotherapy in Subjects with Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs to be Managed by XXX to Evaluate the Safety and Efficacy of an Investigational Product as Monotherapy in Subjects with Partial Epilepsy Unresponsive to Current Antiepileptic Drugs (AED) in Comparison to Historical- Pseudo -Placebo Control Groups

Migraine

A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study of XXX for Migraine Prophylaxis in Patients with Migraine.

A Phase II, Safety, Tolerability, and Efficacy Study of XXX in the Treatment of Acute Migraine Headache

A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of XXX Versus XXX-Containing Combination Medications for the Acute Treatment of Migraine When Administered During the Moderate-Severe Pain Phase of the Migraine

A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of XXX in Adult Migraineurs

A XXX Migraine Study: 2000

CLINICAL TRIAL EXPERIENCE (continued):

Multiple Sclerosis

A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral XXX Extended Release Tablets (5 mg and 10 mg twice daily) in Patients with Multiple Sclerosis

JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with XXX

MS (multiple sclerosis) Trak Study: 1999

Osteoarthritis

A Randomized, Placebo-Controlled Trial of XXX Added to Nonsteroidal Anti-inflammatory Drugs in Patients with Knee Pain due to Osteoarthritis who have had Suboptimal Response to Nonsteroidal Anti-inflammatory Drug Treatment

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of XXX in Subjects with Moderate to Severe, Chronic Knee or Hip Pain From Osteoarthritis

Pain

A Phase II, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety of XXX 20MG and 120MG Twice Daily for 4 Weeks in Patients with Chronic Peripheral Neuropathic Pain

A Phase II, 52-week, Open-label, Long-term Treatment Evaluation of the Safety and Efficacy of XXX in subjects with moderate to severe Chronic Pain

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of XXX in Subjects with Diabetic Painful Neuropathy and Small Fiber Neuropathy Associated with Impaired Glucose Tolerance Followed by a Double-Blind Safety Extension and an Open Label Safety Extension

A Randomized, Double-blind, Placebo-controlled Study of the Effect of a Single Injection of XXX on Reduction of Pain from Vertebral Fracture Associated with Osteoporosis

An Open-label, Multi-center Trial to Assess the Long-term Safety and Efficacy Of XXX in Opioid-experienced Subjects with Chronic Noncancer Pain

A 12-week Placebo-Controlled, Double-Blind, Randomized withdrawal Study to Evaluate the Efficacy and Safety of XXX in Subjects with Moderate to Severe Chronic Low Back Pain

CLINICAL TRIAL EXPERIENCE (continued):

A Randomized Withdrawal, Multi-center, Open-Label, Multiple-Dose, Long-Term Safety Study Randomized, Open-Label, Parallel-Group, Multiple-Dose, Long-Term Safety Study in Subjects with Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

A Phase IIb Repeat Dosing Clinical Trial of XXX in Subjects with Moderately Severe Diabetic Neuropathy

A Randomized, center, Double-Blind, Parallel-Group Trial with Controlled Adjustment of Dose Assessing the Analgesic Efficacy and Safety of a New Analgesic Compared with Placebo in Subjects with Painful Diabetic Peripheral Neuropathy

A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of XXX Vs. Placebo in Reducing the Pain Associated with Post-Herpetic Neuralgia

A Phase II Randomized, Double Blind, Multi-Dose, Active- and Placebo-Controlled, Multi-Center, Parallel Group Study of the Analgesic Effect of XXX in Adult Patients with Chronic Low Back Pain

A Multi-center, Randomized, Double-Blind, Placebo-Controlled, Parallel Study Comparing the Analgesic Efficacy and the Safety of XXX (1 Mg, 2 Mg, And 4 Mg), XXX (60 Mg) and Placebo in Approximately 275 Subjects with Diabetic Neuropathic Pain

Parkinson's Disease

A Placebo-Controlled Study to Evaluate the Safety and Efficacy of XXX in Subjects with Parkinson's Disease

A Randomized, Double-Blind, 2-Way Crossover Study to Compare XXX to Standard Carbidopa-Levodopa and Characterization of Multiple-dose Pharmacokinetics and Pharmacodynamics of XXX in Levodopa-experienced Parkinson's Disease Subjects with Motor Complications

Other Indications

A Prospective, double-blind, placebo-controlled, randomized, multi-center study with an open-label extension period to investigate the efficacy and safety of XXX in the treatment of post-stroke spasticity of the lower limb

A Fixed Dose Randomized, Double-Blind, 12-week Study of XXX Subjects with Moderate to Severe Idiopathic Restless Legs Syndrome

A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of XXX in Stable Patients with Schizophrenia

CLINICAL TRIAL EXPERIENCE (continued):

KEEPER Study: 2001

Saviant Study (Prosoptide): 2003

Fast-MAG Trial. An NIH-NIND-Sponsored clinical Trial to Evaluate Field Initiation of Magnesium Neuroprotective Therapy in Acute Stroke. The FAST-MAG Phase 3 trial is a multicenter, randomized, placebo-controlled, double-blind, parallel group trial of intravenous magnesium sulfate initiated by paramedics in the field within 2 hours of symptom onset in 1700 patients with acute stroke. The primary objective of the study is to evaluate the efficacy and safety of field-initiated magnesium sulfate in improving the long-term functional outcome of patients with acute stroke.

PRESENTATIONS AND GUEST LECTURES:

Stroke, Resident Lecture Series, Department of Family Medicine, Pacific Hospital of Long Beach: 1998; 1999

Neurology Lecture Series, St. Mary Medical Center Long Beach: 1997-2002

Stroke, Resident Lecture, Department of Family Medicine, Harbor-UCLA Medical Center: 1997

Neurology Consultant, Morbidity & Mortality Conference, Department of Internal Medicine, Harbor-UCLA Medical Center, 1996; 1997

Epilepsy, Resident Lecture series, Department of Family Medicine, Harbor-UCLA Medical Center: 1996

Stroke, 1996 Board Review Course for the Examination for Added Qualifications in Geriatric Psychiatry, California Geriatric Education Center, UCLA Multi-campus Program in Geriatric Medicine and Gerontology: 1996

Neurology Clinical Cases, 1996 Board Review for the Examination for Added Qualifications in Geriatric Psychiatry, California Geriatric Education Center, UCLA Multi-campus Program in Geriatric Medicine and Gerontology, 1996

Epilepsy, Transitional Internship Lecture Series, Harbor-UCLA Medical Center 1996

MEMBERSHIPS:

American Academy of Neurology, Active member: 1995 to present

Association of California Neurologists, Active member: 2001-2002

Los Angeles Society of Neurological Sciences, Active member; 1996 to present, former board member

MEMBERSHIPS (continued):

Los Angeles County Medical Association, Associate member: 1995 to present
American Heart Association, Long Beach, board member: 2000-2001
Joint Council of Interns & Residents, executive board member, USC, Harbor-UCLA,
Martin Luther King, Secretary/Treasurer: 1996-1997, Vice President: 1995-1996
Joint Council of Interns & Residents, Harbor-UCLA Medical Center, President: 1995-
1997, Vice President: 1994-1995, Neurology representative: 1993-1997

SPECIAL HONORS:

Teaching Recognition Award, Internal Medicine Residency Program, St. Mary Medical
Center affiliated with UCLA School of Medicine: 1998, 1999, 2001, and 2002
Outstanding Teaching Attending, Internal Medicine Residency Program St. Mary Medical
Center affiliated with UCLA School of Medicine; 1997
Teaching Excellence Award, UCR/UCLA Biomedical Science Program, Harbor-UCLA
Medical Center: 1997
Honor Award for support of resident issues, Joint Council of Interns & Residents: 1999
Chief Resident, Department of Neurology, Harbor-UCLA Medical Center: 1995-1996
Graduated Cum Laude, Baccalaureate of Science, Biomedical Sciences, UC Riverside: 1989
Dean's List, UC Riverside: 1985-1989
Bank of America Award, Mathematics: 1985
Hollywood High School Alumni Scholarship: 1985

VOLUNTARY SERVICE:

Chancellor Place at Chino Hills, Assisted Living and Retirement facility, 2003 to present
St. Mary Medical Center Senior Center: 2000-2004
Pio Pica Elementary School, Santa Ana, Health Day, 2000
Los Angeles Marathon, Physician Volunteer: 1995, 1996, 1997
B.A.P.S. Swaminarayan Hindu Temple, Medical Services for the Community: 1990-2004
American Red Cross, Blood Donation Drive: 1990; 1991; 1992
Big Brothers of Greater Los Angeles: 1995-1997